Form 4: Axsome CCO Ari Maizel Granted 16,385 Restricted Stock Units

Axsome Therapeutics' Chief Commercial Officer, Ari Maizel, received a grant of 16,385 restricted stock units, aligning executive incentives with long-term company performance.

Summary

• Ari Maizel, Chief Commercial Officer of Axsome Therapeutics, Inc. (AXSM), was granted 16,385 Restricted Stock Units (RSUs) on February 26, 2026.
• Each RSU represents a contingent right to receive one share of Axsome's common stock.
• The RSUs will vest over a period, with 25% vesting on February 26, 2027, and the remainder vesting in three substantially equal annual installments, achieving full vesting by February 26, 2030.
• Vested shares will be delivered to the reporting person upon the earlier of a Change in Control, separation of service, or seven years from the grant date (February 26, 2033).
• The grant was made pursuant to the Issuer's 2025 Long-Term Incentive Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive incentive alignment and retention, which is generally favorable for long-term company stability and performance.

Positives

• The grant of Restricted Stock Units to the Chief Commercial Officer aligns management's incentives with the long-term performance and shareholder value creation of Axsome Therapeutics.
• The multi-year vesting schedule encourages executive retention and sustained focus on strategic objectives.

Future Outlook

The vesting schedule indicates a long-term incentive structure designed to retain the Chief Commercial Officer and align their interests with the company's performance through February 2030 and potentially beyond for share delivery.

Management Comments

• Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units with multi-year vesting schedules, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. This practice is common among peers like Biogen (BIIB) or Vertex Pharmaceuticals (VRTX) to incentivize long-term performance and executive retention, especially given the extended development cycles for new therapies.

Comparison to Industry Standards

• The grant of RSUs to a Chief Commercial Officer is a standard practice in the pharmaceutical and biotechnology sectors, comparable to compensation structures at companies such as Gilead Sciences or Amgen.
• The multi-year vesting schedule, with a significant portion vesting over several years, is consistent with industry benchmarks for executive retention and performance alignment. For instance, similar vesting schedules are observed in equity awards at companies like Eli Lilly and Company for their senior executives.
• The inclusion of provisions for accelerated vesting or share delivery upon a Change in Control or separation of service is also a common feature in executive compensation plans across the industry, reflecting standard corporate governance practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive retention and alignment of management interests with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to performance-based compensation.

Next Steps

• Vesting of 25% of RSUs on February 26, 2027.
• Subsequent annual vesting installments until full vesting on February 26, 2030.
• Delivery of vested shares upon specific conditions (Change in Control, separation of service, or seven years from grant date).

Key Dates

Recommendation

This Form 4 filing details a routine executive equity grant and does not present new information that would fundamentally alter the investment thesis for Axsome Therapeutics. While it indicates continued executive alignment, it is not a catalyst for a 'buy' or 'sell' recommendation on its own. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial news.

Keywords

Axsome Therapeutics, AXSM, Restricted Stock Units, RSU, Ari Maizel, Chief Commercial Officer, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Vesting Schedule